Envoy Medical Inc.
COCH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for COCH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COCH
Envoy Medical Inc. is a clinical-stage hearing implant company developing the Acclaim CI, a fully implanted cochlear implant, and is currently awaiting an FDA decision on its PMA application, expected in the second half of 2027.
Key risk: FDA approval uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Envoy Medical Inc..
Envoy Medical Inc. is a clinical-stage hearing implant company developing the Acclaim CI, a fully implanted cochlear implant, and is currently awaiting an FDA decision on its PMA application, expected in the second half of 2027.
- Cash and equivalents were $19.7 million as of June 30, 2026 [sec].
- Total revenue was $0.1 million for the six months ended June 30, 2026 [sec].
- Net loss was $6.0 million for the six months ended June 30, 2026 [sec].
- Shareholders' equity was negative $18.8 million as of June 30, 2026 [sec].
- The company expects an FDA decision on its PMA application for the Acclaim CI in the second half of 2027, assuming no panel review is requested [sec_mda · as of 2026-08-10].
What works
- The company is utilizing a modular PMA pathway for the Acclaim CI, which allows for earlier regulatory feedback and a streamlined review process [sec_mda · as of 2026-08-10].
- Cash increased from $3.7 million at December 31, 2025 to $19.7 million at June 30, 2026, indicating improved liquidity [sec_mda · as of 2026-08-10].
What to weigh
- The company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future [sec_mda · as of 2026-08-10].
- The FDA approval process is uncertain, and there is no guarantee that the Acclaim CI will receive FDA approval; a panel review could extend the decision timeline to the first half of 2028 [sec_mda · as of 2026-08-10].
- Shareholders' equity was negative $18.8 million as of June 30, 2026, indicating accumulated deficits [sec].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026 and December 31, 2025 we had $19,679 and $3,739 of cash, respectively.”
SEC MD&A · August 10, 2026
Expected FDA decision timeline for Acclaim CI
“we currently anticipate obtaining the FDA's decision on our PMA application at some point within the second half of 2027 assuming that no panel review is requested.”
SEC MD&A · August 10, 2026
Uncertainty of FDA approval
“The FDA approval process is uncertain and there can be no guarantees of whether the Acclaim CI will ever successfully receive FDA approval.”
SEC MD&A · August 10, 2026
Net loss and accumulated deficit
“We had a net loss of $4,351 and $4,998 for the three months ended March 31, 2026 and 2025, respectively, and had an accumulated deficit of $319,097”
SEC MD&A · May 11, 2026
Risks & what to watch (4)›
Key risks
- FDA approval uncertainty — No guarantee of FDA approval for Acclaim CI; timeline may extend to first half of 2028 if panel review is requested [sec_mda · as of 2026-08-10].
- Ongoing operating losses — Company expects to continue incurring significant losses as it advances clinical trials and regulatory processes [sec_mda · as of 2026-08-10].
- Negative shareholders' equity — Shareholders' equity was negative $18.8 million as of June 30, 2026, reflecting accumulated deficits [sec].
- Clinical trial risks — Uncertainty in size, duration, and costs of clinical trials; results may not support regulatory approval [sec_mda · as of 2026-08-10].
What to watch
- FDA decision on the Acclaim CI PMA application, expected in the second half of 2027 [sec_mda · as of 2026-08-10].
- Progress of the Acclaim CI pivotal clinical trial and patient enrollment [sec_mda · as of 2026-08-10].
- Changes in cash runway and operating expenses as the company funds clinical development [sec_mda · as of 2026-08-10].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Envoy Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Envoy Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
11.2 months
D/E 6.13 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$2.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,763,344 | $1.2M |
| dsg capital advisors, llc | 625,000 | $416K |
| geode capital management, llc | 521,824 | $347K |
| vanguard fiduciary trust co | 294,721 | $196K |
| arcus capital partners, llc | 187,573 | $125K |
| northern trust corp | 111,050 | $74K |
| morgan stanley | 73,900 | $49K |
| ubs group ag | 70,459 | $47K |
| blackrock, inc. | 47,514 | $32K |
| goldman sachs group inc | 36,462 | $24K |
Showing top 10 of 29 institutional holders of Envoy Medical Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.0%
- Days to cover
- 8.8
- Shares short
- 1,357,337
- Daily short volume (Apr 30, 2026)
- 32.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
COCH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Envoy Medical Inc.?
Envoy Medical Inc. is a clinical-stage hearing implant company developing the Acclaim CI, a fully implanted cochlear implant, and is currently awaiting an FDA decision on its PMA application, expected in the second half of 2027.
What is Envoy Medical Inc.'s lead drug candidate?
Envoy Medical Inc.'s most advanced tracked candidate is acclaim ci (Preclinical) for Severe-to-profound sensorineural hearing loss.
Who is the CEO of Envoy Medical Inc.?
Mr. Brent T. Lucas Esq. is the chief executive officer of Envoy Medical Inc. (COCH).
Where is Envoy Medical Inc. headquartered?
Envoy Medical Inc. (COCH) is headquartered in White Bear Lake, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.